Select Language
ErbB3
ErbB3 Overview
| English Name | Receptor tyrosine-protein kinase erbB-3 | Approved Drugs | 2 |
| Drugs in Clinical Trials | 31 | Target Synonym | EC:2.7.10.1，FERLK，EC 2.7.10，Proto-oncogene-like protein c-ErbB-3，HER3，ERBB3，Erb-B2 Receptor Tyrosine Kinase 3，V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3，Tyrosine Kinase-Type Cell Surface Receptor HER3，Human Epidermal Growth Factor Receptor 3，Lethal Congenital Contracture Syndrome 2，Receptor Tyrosine-Protein Kinase ErbB-3，EC 2.7.10.1，P180-ErbB3，P45-SErbB3，P85-SErbB3，MDA-BF-1，C-ErbB-3，C-ErbB3，ErbB3-S，ErbB-3，LCCS2，Receptor， ErbB-3 |
| Highest Development Stage | Approved | ||
| English Name | Receptor tyrosine-protein kinase erbB-3 |
| Target Synonym | EC:2.7.10.1，FERLK，EC 2.7.10，Proto-oncogene-like protein c-ErbB-3，HER3，ERBB3，Erb-B2 Receptor Tyrosine Kinase 3，V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3，Tyrosine Kinase-Type Cell Surface Receptor HER3，Human Epidermal Growth Factor Receptor 3，Lethal Congenital Contracture Syndrome 2，Receptor Tyrosine-Protein Kinase ErbB-3，EC 2.7.10.1，P180-ErbB3，P45-SErbB3，P85-SErbB3，MDA-BF-1，C-ErbB-3，C-ErbB3，ErbB3-S，ErbB-3，LCCS2，Receptor， ErbB-3 |
| Approved Drugs | 2 |
| Drugs in Clinical Trials | 31 |
| Highest Development Stage | Approved |
ErbB3 Product List
- Product Category
Protein (8)Cell (1)
- Product Status
Launched (9)
- Species
Human (7)Mouse (1)Cynomolgus/Rhesus macaque (1)
- Tag
His Tag (4)Fc Tag (1)Strep Tag (1)Mouse IgG Fc Tag (1)His Tag & Avi Tag (1)- (1)
- Conjugate
Unconjugated (6)FITC Labeled (1)Biotin-labeled (1)- (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT ER3-H5223 |  Human | HEK293 | Human ErbB3 / Her3 Protein, His Tag (MALS verified) |  |  |  |
HOT ER3-H5257 | Human | HEK293 | Human ErbB3 / Her3 Protein, Mouse IgG2a Fc Tag (MALS verified) |  | | |
HOT ER3-H5259 | Human | HEK293 | Human ErbB3 / Her3 Protein, Fc Tag (MALS verified) |  | | |
HOT ER3-H82E6 | Human | HEK293 | Biotinylated Human ErbB3 / Her3 Protein, His,Avitag™ (MALS verified) |  | | |
HOT ER3-M52H5 |  Mouse | HEK293 | Mouse ErbB3 / Her3 Protein, His Tag (MALS verified) |  | | |
CHEK-ATP149 | Human | HEK293 | HEK293/Human ErbB3 Stable Cell Line |  | ||
ER3-H5288 | Human | HEK293 | Human ErbB3 / Her3 Protein, Twin-Strep Tag (MALS verified) |  | | |
ER3-HF2H5 | Human | HEK293 | FITC-Labeled Human ErbB3 / Her3 Protein, His Tag |  | | |
ER3-C52H3 | Cynomolgus/Rhesus macaque | HEK293 | Cynomolgus/Rhesus macaque ErbB3 / Her3 Protein, His Tag (MALS verified) |  | | |
Total: 9
- 1
ErbB3 Background
ErbB3,also known as Her3 (human epidermal growth factor receptor 3), is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound glycoprotein has a neuregulin binding domain but has not an active kinase domain. It therefore can bind the ligand but cannot mediate the intracellular signal transduction through protein phosphorylation. However, it does form heterodimers with ErbB2 or other EGFR members responsible for tyrosine phosphorylation to give a receptor complex and initiate the related pathway, which lead to cell proliferation or differentiation. Overexpression of this protein has been reported in numerous cancers, including prostate, bladder, and breast tumors. This protein has different isoforms derived from alternative splicing variants, and among which, the secreted isoform lacking the intermembrane region modulates the activity of membrane-bound form.
ErbB3 Synonyms
ERBB3,HER3,LCCS2,MDA-BF-1,MGC88033,c-erbB3,erbB3-S,p180-ErbB3,p45-sErbB3,p85-sErbB3
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Izalontamab | SI-B001; SI-1X6.4 | Phase 3 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Neoplasms, Glandular and Epithelial; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| JSKN-016 | JSKN-016; JSKN016 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| YL-202 | YL-202; BNT326 | Phase 3 Clinical | MediLink Therapeutics Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms | Details |
| SHR-A2009 | SHR-A2009 | Phase 3 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Solid tumours; Triple Negative Breast Neoplasms | Details |
| Patritumab Deruxtecan | U3-1402; U3-1402a; MK-1022 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| Nezutatug | HMBD-001 | Phase 2 Clinical | Hummingbird Bioscience | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| Sapitinib | AZD-8931 | Phase 2 Clinical | Astrazeneca Plc | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Allitinib Tosylate | AST-6; ALS-1306; AST-1306 | Phase 2 Clinical | Shanghai Allist Pharmaceutical Technology Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| HMBD-501 | ENV-501; HMBD-501; ENV-ONC-501 | Phase 2 Clinical | Hummingbird Bioscience | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Skin Melanoma | Details |
| JS-212 | JS212; JS-212 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Solid tumours | Details |
| DB-1418 | AVZO-1418; DB-1418 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Lung Neoplasms; Neoplasms, Glandular and Epithelial; Solid tumours | Details |
| 89Zr-Patritumab deruxtecan | Phase 2 Clinical | Daiichi Sankyo Co Ltd, Daiichi Sankyo Inc, The Netherlands Cancer Institute | Carcinoma, Non-Small-Cell Lung | Details | |
| IBI-133 | IBI133; IBI-133 | Phase 2 Clinical | Solid tumours | Details | |
| DB-1310 | DB-1310 | Phase 2 Clinical | Duality Biologics (Shanghai) Co Ltd, Duality Biologics (Suzhou) Co Ltd | Neoplasm Metastasis; Solid tumours | Details |
| SIBP-03 | SIBP-03 | Phase 2 Clinical | Shanghai Institute of Biological Products Co Ltd | Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| JK-07 (SalubrisBio) | JK07; SAL007; SAL-007 | Phase 2 Clinical | Salubris Biotherapeutics Inc | Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Pulmonary Arterial Hypertension | Details |
| Recombinat humanized HER3-targeting antibody | Phase 2 Clinical | Shanghai Institute of Biological Products Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details | |
| Elgemtumab | NOV-6; LJM-716 | Phase 1 Clinical | Morphosys Ag, Novartis Pharma Ag | Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| MP-0274 | DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274 | Phase 1 Clinical | Molecular Partners Ag | Neoplasms | Details |
| AV-203 | AV-203; CAN-017 | Phase 1 Clinical | Aveo | Neoplasms; Solid tumours | Details |
| HDM-2024 | HDM2024; HDM-2024 | Phase 1 Clinical | Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd | Solid tumours | Details |
| KHN-922 | KHN-922 | Phase 1 Clinical | Chengdu Kanghong Pharmaceutical Group Co Ltd | Neoplasms; Solid tumours | Details |
| Sirotinib Maleate | XZP-5491 | Phase 1 Clinical | Shandong Xuanzhu Pharmaceutical Technology Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Stomach Neoplasms | Details |
| PM1300 | PM-1300; PM1300 | Phase 1 Clinical | Neoplasms | Details | |
| AK-138-D-1 | AK138D1; AK-138-D-1 | Phase 1 Clinical | Neoplasms; Solid tumours | Details | |
| BL-B16D1 | BLB16D1; BL-B16D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| SYS-6023 | SYS-6023; SYS6023 | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Breast Neoplasms; Metastatic breast cancer; Solid tumours | Details |
| AMT-562 | AMT-562 | Phase 1 Clinical | Multitude Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| SIBP-A13 | SIBP-A13 | Phase 1 Clinical | Shanghai Institute of Biological Products Co Ltd | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Metastatic breast cancer; Solid tumours | Details |
| Recombinant human ErbB3 fragment vaccine (Zensun) | rhErbB3-f | Phase 1 Clinical | Zensun (Shanghai) Sci&Tech Co Ltd | Neoplasms | Details |
| DM-002 | DM-002; DM002 (Danma) | Phase 1 Clinical | Danma (Suzhou) Biomedical Technology Co Ltd | Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Solid tumours | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Osimertinib Mesylate | AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 | Approved | Astrazeneca Plc | 泰瑞沙, Tagrisso | United States | Carcinoma, Non-Small-Cell Lung | Astrazeneca Pharmaceutical Co Ltd | 2015-11-13 | Adenocarcinoma; Adenocarcinoma of Lung; Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Meningeal Neoplasms; Multiple Myeloma; Neoplasm, Residual; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | Details |
| Zenocutuzumab | MCLA-128 | Approved | Merus Nv | Bizengri | United States | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung | Merus Nv | 2024-12-04 | Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: